Skip to main content
. Author manuscript; available in PMC: 2014 Aug 1.
Published in final edited form as: Bioorg Med Chem Lett. 2013 May 29;23(15):4398–4403. doi: 10.1016/j.bmcl.2013.05.072

Figure 4.

Figure 4

Inhibition of cell survival in RD and RH30 rhabdomyosarcoma cell lines for potent Yes1 kinase inhibitors saracatinib (A, IC50[RH30] = 10.1 µM), AMG-Tie-2-1 (B, IC50[RD] = 10.5 µM, IC50[RH30] = 6.0 µM), and AZ-23 (C, IC50[RD] = 5.3 µM, IC50[RH30] = 1.8 µM).